PBYI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Puma Biotechnology Inc (PBYI) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock's technical indicators, insider and hedge fund selling trends, and lack of strong positive catalysts suggest caution. While the company has shown revenue growth, its declining net income, EPS, and gross margin, combined with a lack of recent congressional trading data and weak trading sentiment, do not support a compelling buy case currently.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 39.992, showing no clear signal. Moving averages are converging, suggesting indecision in price trends. The stock is trading near its support level of 5.816, with resistance at 6.649 and 7.482.
The company reported a 27.72% YoY revenue increase in Q4 2025, with royalty revenue significantly up due to increased shipments to China. Enrollment in Phase II trials for alisertib is progressing faster than expected.
Hedge funds and insiders are selling heavily, with insider selling up 230.93% in the last month. The stock has a 60% chance to decline 1.94% in the next day and 15.93% in the next month. Financial metrics such as net income, EPS, and gross margin have declined YoY. No recent congressional trading data or strong analyst upgrades.
In Q4 2025, revenue increased by 27.72% YoY to $75.5 million. However, net income dropped by 30.39% YoY to $13.44 million, and EPS decreased by 33.33% YoY to 0.26. Gross margin also fell by 9.28% YoY to 69.35%.
No recent analyst rating or price target changes were provided. Wall Street sentiment appears neutral to slightly negative based on the lack of upgrades and the stock's weak performance.
